DNA sensors in metabolic and cardiovascular diseases: Molecular mechanisms and therapeutic prospects

Summary DNA sensors generally initiate innate immune responses through the production of type I interferons. While extensively studied for host defense against invading pathogens, emerging evidence highlights the involvement of DNA sensors in metabolic and cardiovascular diseases. Elevated levels of modified, damaged, or ectopically localized self‐DNA and non‐self‐DNA have been observed in patients and animal models with obesity, diabetes, fatty liver disease, and cardiovascular disease. The accumulation of cytosolic DNA aberrantly activates DNA signaling pathways, driving the pathological progression of these disorders. This review highlights the roles of specific DNA sensors, such as cyclic AMP‐GMP synthase and stimulator of interferon genes (cGAS‐STING), absent in melanoma 2 (AIM2), toll‐like receptor 9 (TLR9), interferon gamma‐inducible protein 16 (IFI16), DNA‐dependent protein kinase (DNA‐PK), and DEAD‐box helicase 41 (DDX41) in various metabolic disorders. We explore how DNA signaling pathways in both immune and non‐immune cells contribute to the development of these diseases. Furthermore, we discuss the intricate interplay between metabolic stress and immune responses, offering insights into potential therapeutic targets for managing metabolic and cardiovascular disorders. Understanding the mechanisms of DNA sensor signaling in these contexts provides a foundation for developing novel interventions aimed at mitigating the impact of these pervasive health issues.